5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

5567 Background: Cetuximab in combination with platinum and 5FU has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …

6066 Background: Treatment options for patients with squamous cell cancer of the head and
neck (SCCHN) are limited. Cetuximab, an antiepidermal growth factor receptor monoclonal …

Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab
maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment …

Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …

5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …

5537 Background: The epidermal growth factor receptor (EGFR) is expressed in nearly all
SCCHN and carries a strong prognostic significance, providing the rationale for using EGFR …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …

5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …